# Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

> **NCT00090974** · — · COMPLETED · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00090974
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01-26
- **Primary completion:** 2013-01-30
- **Final completion:** 2013-01-30
- **Target enrollment:** — (—)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090974, "Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00090974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*